Meeting
2023 ASCO Breakthrough
Long-term survival outcome of radiation therapy for unresectable, locally advanced non-small cell lung cancer: Single center experience at Hospital 175.
Authors
Nam Vu
Yamanashi University, Chou, Japan
Nam Vu , Dao Tien Manh , Nguyen Viet Cuong , Nguyen Hong Son , Tran Quoc Viet , Hiroshi Onishi Sr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Advanced Disease
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 142)
DOI
10.1200/GO.2023.9.Supplement_1.142
Abstract #
142
Poster Bd #
H4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.
First Author: Ghanashyam Biswas
Poster
2023 ASCO Genitourinary Cancers Symposium
Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation.
First Author: Carlos Riveros
Poster
2021 ASCO Annual Meeting
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
First Author: David R. Spigel
Poster
2019 ASCO Annual Meeting
Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
First Author: Atsushi Horiike